ANALYSIS: Inside The Sun-Novartis Japan Deal
This article was originally published in PharmAsia News
Executive Summary
Like all pharma transactions, the Sun-Novartis deal in Japan took its time to come to fruition – around six months from conceptualization is a fair guesstimate.
You may also be interested in...
India-Japan Partnering Momentum: Regulatory Alignment Is Key
Biopharma executives from India and Japan discuss the need for enhanced “alignment” on the regulatory front, including exploring the possibility of a mutual recognition agreement as the two nations seek to expand biopharma partnering efforts and also build supply chain resilience.
Lupin Buys Shionogi Brands As Japan Market Opens To Indian Firms
Kyowa, the Japanese arm of Indian major Lupin, is buying a basket of mature products including CNS drugs Rhythmy and Resmit from Shionogi. As innovator companies seek to shed older products in Japan, generic firms, especially Indian ones, are taking advantage to expand in the world's second largest pharmaceutical market.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.